The US Association for Accessible Medicines has continued to criticize the Biden administration’s proposed Build Back Better Act due to the negative affect it could have on the biosimilars industry. The organization maintains that, as it currently stands, allowing free biosimilar competition will achieve more savings for patients than Build Back Better’s price negotiation model.
Under the proposal, the Department of Health and Human Services would have the authority to negotiate drug prices with manufacturers,...
